Pelareorep + FOLFIRI + Bevacizumab
Second-Line KRAS-mutant MSS Metastatic Colorectal Cancer (mCRC)
Phase 2Completed (REO 022) - Planning confirmatory study
Key Facts
Indication
Second-Line KRAS-mutant MSS Metastatic Colorectal Cancer (mCRC)
Phase
Phase 2
Status
Completed (REO 022) - Planning confirmatory study
Company
About Oncolytics Biotech
Oncolytics Biotech is advancing pelareorep, a unique oncolytic virus that selectively replicates in cancer cells and stimulates a systemic anti-tumor immune response. The company's strategy is centered on GI cancers, where it has generated compelling clinical data, including a 62% objective response rate in first-line mPDAC and more than doubled survival benchmarks in KRAS-mutant mCRC. With a seasoned leadership team and a clear focus on registration-enabling studies, Oncolytics aims to bring a novel, tolerable immunotherapy to patients facing devastating GI malignancies.
View full company profile